iCAD To Report First Quarter 2018 Financial Results on Monday, May 14, 2018

NASHUA, N.H. (May 8, 2018) – iCAD, Inc. (NASDAQ: ICAD), an
industry-leading provider of advanced image analysis, workflow solutions and
radiation therapy for the early identification and treatment of cancer, today
announced that it will release financial results for the first quarter ended
March 31, 2018 after the close of the market, and host a conference call at
4:30 pm Eastern Time, on Monday, May 14, 2018.

Monday, May 14th @ 4:30pm Eastern Time

In addition, a replay of the call will remain on the
Company’s website (www.icadmed.com) until the Company releases its second
quarter 2018 financial results.

About iCAD, Inc.

iCAD delivers innovative cancer detection and radiation therapy
solutions and services that enable clinicians to find and treat cancers earlier
and faster while improving patient outcomes. iCAD offers a comprehensive range
of upgradeable computer aided detection (CAD) and workflow solutions to support
rapid and accurate detection of breast and colorectal cancers. iCAD’s Xoft® Axxent®
Electronic Brachytherapy (eBx®) System® is a painless, non- invasive technology
that delivers high dose rate, low energy radiation, which targets cancer while
minimizing exposure to surrounding healthy tissue. The Xoft System is FDA
cleared and CE marked for use anywhere in the body, including treatment of non-melanoma
skin cancer, early-stage breast cancer and gynecological cancers. The
comprehensive iCAD technology platforms include advanced hardware and software
as well as management services designed to support cancer detection and
radiation therapy treatments. For more information, visit or www.icadmed.com or www.xoftinc.com.

CONTACTS:

Media Inquiries:

ARPR, LLC

Erin Bocherer

(855) 300-8209 x120

erin@arpr.com

or

Investor Relations: LifeSci Advisors Jeremy Feffer (212)
915-2568
jeremy@lifesciadvisors.com